Comment
Author: Admin | 2025-04-28
Or addictions. Ar/mod is generally classified as a psychostimulant.1,2 Psychostimulants may be associated with seizures, even at therapeutic doses,3 and some patients, such as those with ADHD, may be at higher risk of this psychostimulant-associated adverse effect.4,5 So, is ar/mod associated with an increased risk of seizures? This question assumes importance when either of these drugs is considered indicated for a patient who has a current or past history of seizure disorder or who has risk factors for seizures (such as a past history of head injury or current treatment with a drug that lowers the seizure threshold).ApproachesThere is no formal guidance on the safety of ar/mod in patients with current or past history of seizure disorder or those with risk factors for seizures. This article therefore examines approaches to the situation. Direct approaches involve searching the prescribing information, checking electronic databases such as PubMed, and writing to the drug manufacturer for additional information. Indirect approaches involve examining the safety profile of the drug in vulnerable populations and in overdose. Animal data can provide specific clues about the effect of the drug on the seizure threshold. A tentative conclusion can be drawn from a synthesis of the information obtained.Consulting the Prescribing InformationThe first step is to consult the prescribing information, available from the manufacturer’s website for each drug. There is no warning in the prescribing information regarding the use of either drug in seizure disorders, nor report of seizures as an adverse reaction at recommended doses or in overdose (this is easily determined by searching the prescribing information electronic documents for words such as epilepsy, seizure, and fit).Writing to the ManufacturerOfficial drug websites provide a manufacturer “Contact us” option with street address, e-mail address, and telephone numbers listed. The contact options and, indeed, the manufacturer identity could vary across countries and between generic and branded labels of a drug. Contacting one manufacturer of modafinil in November 2015 (with an inquiry about the safety of the drug in seizure disorders) elicited a swift response (within 24 hours) that listed the results of a PubMed search along with a statement that the
Add Comment